Sibylla Biotech

Executive Summary

Sibylla Biotech is an Italian preclinical biotech developing a novel small-molecule discovery platform based on the PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediates Targeting) paradigm. This approach targets folding intermediates of proteins to induce their inactivation, enabling drugging of previously undruggable targets across therapeutic areas. Founded in 2016, the company has built a proprietary platform with potential applications in oncology, neurology, and other diseases. As a preclinical-stage company, Sibylla is focused on advancing its pipeline of small molecules toward IND-enabling studies, leveraging its technology to address high-unmet medical needs. The platform's broad applicability and novel mechanism position Sibylla as an innovative player in the targeted protein degradation space, though it faces typical early-stage risks including funding requirements and validation timelines.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round completion70% success
• Q4 2026Lead candidate selection for first therapeutic program60% success
• Q1 2027Presentation of preclinical proof-of-concept data at major conference50% success